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Fourth universal definition of myocardial 
infarction: Key takeaways
The fourth universal definition of myocardial 
infarction (MI) [1] introduces several changes and 
new concepts of MI to enhance clinical practice. 
The most important of them being, in the opinion 
of the authors herein, the distinction between MI 
and myocardial injury as well as an emphasis on 
the utility of imaging techniques — cardiovascular 
magnetic resonance (CMR) in defining etiology of 
myocardial injury and coronary computed tomo-
graphy angiography in the diagnosis of MI.
The clinical definition of MI specifies: the 
presence of acute myocardial injury detected 
by abnormal cardiac biomarkers in the setting 
of evidence of acute myocardial ischemia [1].
In clinical practice, cardiac troponin I and tro-
ponin T (the latter sometimes derives from skeletal 
muscles [2–4]) are recommended, especially in high-
sensitivity cardiac troponin I (hs-cTn), mainly due 
to its specificity to the heart and sensitivity [5, 6]. 
Of note, for the first time, the acute myocardial inju-
ry was defined clearly as detection of elevated car-
diac troponin values above the 99th percentile upper 
reference limit (URL) and occurrence of the rise 
and/or fall of focused cardiac troponin values [6]. 
Subsequently, without the concomitant rise and/or 
fall in the mentioned biomarker values, can only 
define chronic myocardial injury [7].
The authors emphasize the broad spectrum 
of clinical scenarios leading to myocardial injury, 
ranging from anemia, ventricular tachyarrhythmia, 
heart failure, kidney disease, and hypotensive 
shock to hypoxemia or other comorbidities (Fig. 1). 
However, without clinical evidence of acute is-
chemic myocardial injury, they should remain 
named “myocardial injury” in everyday practice.
For practical reasons, the authors emphasize 
the role of distinguishing between myocardial 
injury and infarction [1, 8]. The differences are 
presented in Figure 2. 
Types of myocardial infarctions
The types of MIs were kept, and are presented 
clearly in Figure 2. Type 1 MI is defined as: the 
detection of a rise and/or fall of cTn with at least 
one value above the 99th percentile URL and with 
at least one of the following:
 — symptoms of acute myocardial injury;
 — new ischemic electrocardiography changes;
 — development of pathological Q waves;
 — imaging evidence of new loss of viable myocar-
dium or new regional wall motion abnormal-
ity in a pattern consistent with an ischemic 
etiology;
 — identification of a coronary thrombus by an-
giography including intracoronary imaging or 
by autopsy [1].
The criteria for type 2 MI do not include 
identification of coronary thrombus due to its 
mechanism — it develops secondarily to another 
illness or process. Possible mechanisms of imbal-
ance between oxygen demand and oxygen supply 
can be fixed coronary atherosclerosis, coronary 
spasm, coronary embolism, coronary artery dis-
section, sustained tachyarrhythmia, severe brady-
arrhythmia, severe hypertension, respiratory 
failure, shock, severe anemia or hypotension [8]. 
For the sake of patients, it is worth noticing that 
in this group, patient treatment should be based 
on restoration of the balance between oxygen de-
mand and supply, through different interventions, 
concerning its primary cause, for instance heart-
rate control, blood pressure-lowering or volume 
adjustment [8, 9]. 
Herein, the aim is to emphasize a fundamental 
issue concerning this document — differences 
between type 1 MI, type 2 MI, and non-ischemic 
myocardial injury.
Type 3 MI is very rare, constituting 3–4% 
of all MIs [10]. The authors highlight the dif-
ference between type 3 MI, it means death 
from probable cardiac reasons and sudden death 
















Figure 1. Spectrum of myocardial injury — from no 
injury to myocardial infarction; cTn — cardiac troponin; 
AMI — acute myocardial infarction.
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frequent). Of note, when autopsy finds fresh 
or recent thrombus in the myocardial infarct-
-related artery, one should confirm type 1 MI 
instead of type 3 MI [11, 12].
The document clarifies the difference between 
periprocedural myocardial injury and MI, both per-
cutaneous coronary intervention (PCI) and coro-
nary artery bypass grafting (CABG). Consequently, 
it emphasizes the role of cardiac biomarkers’ level 
and stability, before further evaluations and prior 
to regarding as a reference level for a particular 
patient. The situation in which an increased level 
of a cardiac biomarker is potentially the result of 
the MI and not the procedures mentioned above 
[13]. The diagnosis of a periprocedural myocardial 
injury requires:
 — increase in cardiac biomarkers (cTn) level, when 
initially patient presents normal values or;
 — increase in cardiac biomarkers (> 20%), when 
initially patient shows its values above the 
99th percentile URL.
For periprocedural (≤ 48 h) MI related to the 
PCI (type 4a MI) and CABG (type 5 MI), five times 
and ten times increase in cTn value is required, 
respectively, if the patient presents normal initial 
values. These conditions are presented in Figure 3. 
In case of initial values of cTn above 99th percentile 
URL, a 20% rise is demanded, and the final value 
higher than five times 99th percentile URL or ten 
times 99th percentile URL in case of CABG. They 
must, of course, be accompanied by one of the 
known clinical criteria [1]. 
Figure 2. Scheme to distinguish myocardial injury and myocardial infarction and particular types of myocardial infarc-
tion; cTn — cardiac troponin; ECG — electrocardiogram; URL — upper reference limit.
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The definition of type 4c MI, connected with 
focal or diffuse restenosis after PCI, is based on 
a rise and/or fall of cTn values above the 99th per-
centile URL and definition based on the recognition 
of type 1 MI [1].
Myocardial injury and  
infarction associated  
with non-cardiac procedures
The occurrence of asymptomatic perioperative 
MI is strongly associated with 30-day mortality [14, 
15]. Increased oxygen demand in the perioperative 
period and predominant etiology of myocardial 
ischemia are well recognized and the fact that 
about 35% of patients reveal hs-cTn level above 
the 99th percentile URL in post-operative blood 
samples [16, 17]. Therefore, increased vigilance 
is demanded in all high-risk individuals, and their 
baseline pre-operative value is necessary to collect.
Myocardial infarction with  
non-obstructive coronary arteries
The document also highlights the diagnosis 
of myocardial infarction with non-obstructive 
coronary arteries (MINOCA; ≤ 50% diameter 
stenosis in a major epicardiac vessel) [1]. The 
prevalence of MINOCA depends on sex (it occurs 
more frequently in women than men), the type of 
MI (it is more common in non-ST-segment eleva-
tion myocardial infarction [NSTEMI] than in ST-
-segment elevation myocardial infarction [STEMI]), 
and it concerns about 6–8% of patients with MI [18]. 
Multiple pathomechanisms underlie this condition 
and the heterogeneous group involves both coronary 
and non-coronary causes. The first authoritative 
international expert definition of MINOCA was 
published in the European Society of Cardiology 
working group position paper [18, 19]. Recently, 
the 2020 non-ST-segment elevation-acute coronary 
syndrome (NSTE-ACS) guidelines have maintained 
the approach to MINOCA as ‘working diagnosis’ [20] 
and the authors have proposed a clinical algorithm 
to aid in the diagnosis. The proposed ‘traffic light’ 
scheme includes different imaging tools such as 
echocardiography, cardiac ventriculography, CMR, 
intravascular imaging (intravascular ultrasonogra-
phy [IVUS] or optical coherence tomography [OCT]) 
and intracoronary functional testing (acetylcholine 
or ergonovine). The most important recommenda-
tion seems to be to perform CMR in all MINOCA 
patients without an apparent underlying cause [20]. 
Patients with MINOCA can fulfil the criteria of MI 
type 1 and type 2 [21]. It should be stated that the 
current definition excludes Takotsubo syndrome 
(TTS) and myocarditis [20]. 
Takotsubo syndrome
According to available research, the authors 
underline for the first time, the relevance of TTS. 
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Figure 3. Concentration of cardiac troponin in different clinical scenarios relevant to revascularization procedures; 
cTn — cardiac troponin; CABG — coronary artery bypass grafting; PCI — percutaneous coronary intervention; URL — 
upper reference limit.
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They focus on the discrepancy between the usually 
modest and transient increases in cTn values and 
the large territory of electrocardiography changes 
or left ventricle regional akinesis or hypokinesis 
including apical (82% of patients), mid-ventricular 
(14.6%), basal (2.2%), or focal (1.5%) territory. In 
TTS, the coronary arteries are usually angiographi-
cally intact while left ventriculography presents 
above mentioned regional wall motion abnor-
malities — in 10–15% of patients [1]. On the other 
hand, recently published analysis from the largest 
InterTAK Registry concludes that coronary artery 
disease may coexist in TTS patients, presents with 
the whole spectrum of coronary pathology includ-
ing acute coronary occlusion, and is associated 
with adverse outcome [19]. Thus, the differential 
diagnosis with MI can be challenging [20, 21]. 
Consequently, unlike the previous attitude 
to TTS [19], the current guidelines classify it as 
‘other causes of myocardial injury’ [1] or ‘specific 
non-MINOCA status’ [21]. However, TTS’s diag-
nosis cannot be certainly stated in the acute phase 
because imaging follow-up is essential to prove the 
recovery of left ventricular function [21].
Spontaneous coronary dissection
Spontaneous coronary dissection (SCAD) 
leading to blood accumulation within the artery’s 
false lumen with potential compression of the 
true lumen is an important non-atherosclerotic 
condition of MI [1]. It is triggered by vasa vasorum 
hemorrhage or intimal tear [21]. The NSTE-ACS 
guidelines specify three angiographic types of 
SCAD: type 1 with multiple radiolucent lumen, 
type 2 with long diffuse or smooth stenosis, and 
type 3 with focal or tubular stenosis [20]. The dis-
section coexisting with acute myocardial injury and 
evidence of ischemia is type 2 of MI. If coronary 
arteries are non-obstructive (stenosis < 50%) 
the criteria of MINOCA are fulfilled [1, 21]. SCAD 
can be missed on coronary computed tomography 
angiography, therefore OCT or IVUS are applicable 
in unclear clinical scenarios [21].
Cardiac magnetic resonance imaging
The accuracy of CMR provides an unequivocal 
assessment of the etiology of myocardial injury, 
allowing the repeated distinction between acute 
vs. chronic myocardial injury. It also identifies the 
presence and involvement of myocardial inflam-
mation, thus providing a clear distinction between 
ischemic scar/fibrosis (extending from subendo-
cardium to endocardium) and non-ischemic scar/ 
/fibrosis (subepicardial, mid-wall, insertion points) 
in myocardial injury (Fig. 4) [1]. 
COVID-19 and myocardial infarction
Since the initial outbreak of the novel coro-
navirus disease — severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2)/coronavirus 
disease 2019 (COVID-19) — in December 2019, 
data from many countries (Italy, Spain, Switzer-
land, The United States of America) underline 
a dramatic drop in the number of ACS referrals to 
cardiovascular centers at the time of the COVID-19 
outbreak, moreover reduction of PCI in STEMI 
patients was 38% [22–25]. In addition, Legutko 
et al. [26] and Siudak et al. [27] showed a greater 
decline in the number of procedures for NSTEMI, 
unstable angina or chronic coronary syndrome 
than in those for STEMI (19.2% vs. 16.2%). What 
is more, the decline of PCI procedures in NSTEMI 
after lockdown reached about 30% [27]. Of course, 
the obvious consequence of this situation is the 
staggering growth in MI complications, such as 
increased morbidity and mortality. Among the 
Figure 4. The different patterns of scarring in post-con-
trast cardiac magnetic resonance images — late-gado-
linium enhancement.
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mechanisms potentially decreasing admission to 
hospitals during the COVID-19 pandemic are: 
fear of contagion, relaxing lifestyle, decrease of air 
pollution, increase in pain threshold, which leads 
to a higher prevalence of silent or near silent MIs 
[28]. The need for urgent treatment according 
to the guidelines while maintaining the safety of 
medical personnel is necessary. Of note, invasive 
coronary angiography in acute ST-segment eleva-
tion coronary syndrome cannot be neglected, even 
in COVID-19 patients with myocarditis pretending 
to be ACS.
Key points from STEMI  
and NSTE-ACS guidelines 
STEMI
 — Some patients with coronary artery occlusion 
or global ischemia do not have typical ST-seg-
ment elevation in ECG. However, patients with 
clinical manifestation of ongoing myocardial 
ischemia and other ECG patterns (e.g., bundle 
branch block, ventricular pacing, hyperacute 
T-waves, isolated ST-segment depression in 
anterior leads, and/or universal ST-segment 
depression with ST-segment elevation in aVR) 
should be qualified for a primary PCI. 
 — Non-invasive imaging in STEMI patients plays 
a crucial role in the acute phase and during 
long-term management.
 — The MINOCA coexisting with ST-segment 
elevation in ECG requires additional tests to 
diagnose the etiology and tailor proper man-
agement [29].
NSTE-ACS
 — Myocyte injury is related to the release of 
troponin as intracellular protein into the sys-
temic circulation and elevated troponin level is 
a marker of myocardial injury, not only 
a marker of MI. Troponin results should be 
interpreted in the clinical context. 
 — Patients with MINOCA can fulfil the crite-
ria of MI type 1 and type 2 [21]. The 2020 
NSTE-ACS guidelines have proposed a clinical 
algorithm to aid in the diagnosis of MINOCA, 
including different imaging tools such as echo-
cardiography, cardiac ventriculography, CMR, 
intravascular imaging (IVUS or OCT) and 
intracoronary functional testing (acetylcholine 
or ergonovine). The most important recom-
mendation seems to be to perform CMR in 
all MINOCA patients without an apparent 
underlying cause [20]. 
 — hs-cTn assays have a higher negative predictive 
value for acute MI than standard troponin tests.
 — Higher sensitivity and diagnostic accuracy for 
the diagnosis of MI enables shortening the 
time interval between the first and second 
hs-cTn assessment. The 0 h/1 h rule-in or 
rule-out algorithm first and 0 h/2 h second 
should be chosen. The cut-off values within 
both protocols are assay-specific and baseline 
level, acute change must be taken into account 
(1hD or 2hD). Additional blood draw after 3 h 
should be done if previous troponin assess-
ment (0 h/1 h) is inconclusive and clinical 
status still suggests ACS. A rule-out 0 h/3 h 
protocol is still recommended but with the 
lower level of recommendation [20].
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